CD40L-augmented Tumor Infiltrating Lymphocytes (H Lee Moffitt Cancer Center & Research Institute)

CD40L增强的肿瘤浸润淋巴细胞（H Lee Moffitt Cancer Center & Research Institute）

Report date: 2026/04/17 10:36:23

Base Information

Drug NameCD40L-augmented Tumor Infiltrating Lymphocytes (H Lee Moffitt Cancer Center & Research Institute)
Drug Alias NameCD40L TIL（H Lee Moffitt Cancer Center & Research Institute）
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionLymphocyte replacementsCD40 ligand modulators
TargetsCD40 ligand
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research Institute
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A